Entera Bio (NASDAQ:ENTX) Shares Climb 7.8% - Here's Why

Key Points

• Entera Bio shares rose 7.8% to $2.89 in Monday trading, with roughly 662,000 shares changing hands—below the stock’s average daily volume.
• Analyst sentiment is mixed but leans positive: Entera Bio has a consensus “Moderate Buy” rating and a $9.60 price target, including Guggenheim’s $11 target, though Weiss Ratings maintained a sell rating.
• The clinical-stage biopharmaceutical company missed quarterly earnings expectations, reporting a $0.14 per-share loss versus the estimated $0.08 loss. Its pipeline focuses on orally delivered biologics, including treatments for osteoporosis and hypoparathyroidism.

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report)'s share price rose 7.8% during trading on Monday. The company traded as high as $2.89 and last traded at $2.89. Approximately 661,753 shares were traded during mid-day trading, a decline of 34% from the average daily volume of 1,005,796 shares. The stock had previously closed at $2.68.

Analysts Set New Price Targets

ENTX has been the subject of a number of analyst reports. Cantor Fitzgerald initiated coverage on Entera Bio in a research note on Tuesday, September 22nd. They set an "overweight" rating for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Entera Bio in a research note on Thursday. HC Wainwright reissued a "buy" rating on shares of Entera Bio in a research report on Wednesday, June 24th. Guggenheim began coverage on shares of Entera Bio in a report on Thursday, September 24th. They issued a "buy" rating and a $11.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Entera Bio to a "sell" rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Entera Bio currently has an average rating of "Moderate Buy" and a consensus price target of $9.60.

Entera Bio Stock Performance

The stock has a market capitalization of $503.50 million, a P/E ratio of -8.27 and a beta of 1.40. The stock has a 50-day moving average price of $2.88 and a two-hundred day moving average price of $2.02.

Entera Bio (NASDAQ:ENTX - Get Free Report) last announced its earnings results on Friday, August 7th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.06). Equities analysts anticipate that Entera Bio Ltd. will post -0.40 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Entera Bio

An institutional investor recently raised its stake in Entera Bio stock. Seven Fleet Capital Management LP raised its position in shares of Entera Bio Ltd. (NASDAQ:ENTX - Free Report) by 51.9% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 205,542 shares of the company's stock after acquiring an additional 70,224 shares during the quarter. Seven Fleet Capital Management LP owned approximately 0.42% of Entera Bio worth $228,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 14.11% of the company's stock.

About Entera Bio

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered biologic medicines. The company's proprietary platform is designed to enable the oral administration of large-molecule therapies, including peptides and proteins that are traditionally delivered by injection.

Entera Bio's pipeline has included EB613, an oral formulation of parathyroid hormone fragment (teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral parathyroid hormone product intended for hypoparathyroidism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.